Full 2L QBank
Pharmacology Targeted Anticancer Drugs and Immunosuppressants 8044b3bf

Which of the following statements about baricitinib is FALSE?

A
Oral JAK inhibitor
B
Approved for use in moderate to severe Crohn's disease
C
Increases triglycerides
D
Dose reduction is required in renal and hepatic impairement
High-Yield Explanation
Baricitinib andtofacitinib are oral JANUS kinase inhibitors (JAK). These drugs are used in rheumatoid ahritis.Tofacitinib is also used in ulcerative colitis. Major side-effects of these drugs are:* Increased risk of infection: TB , Herpes zoster.* Increased risk of malignancy like Lymphoma.* Hyperiglyceridemia.They require dose reduction in kidney and liver failure. So, they are avoided in lymphopenia and anemia.So, the answer is 'B' because it is not used in Crohn's disease.

Related Pharmacology MCQs

Practice 2,00,000+ NEET PG Questions Free

Timed mock tests, mistake queue analytics, audio lectures & zero attempt limits on i❤️Exams.

Start Free Mock Test Now